Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.10.2012 | main topic | Ausgabe 19-20/2012

Wiener Medizinische Wochenschrift 19-20/2012

The role of nuclear medicine in differentiated thyroid cancer

Wiener Medizinische Wochenschrift > Ausgabe 19-20/2012
MD Susanne Kohlfürst


In differentiated thyroid cancer (DTC) nuclear medicine is able to cover the spectrum from diagnosis and treatment to follow up keeping patient’s management in one institution. Nowadays, DTC is often diagnosed per chance, presenting as small indolent nodule diagnosed on routinely performed ultrasound. Ultrasound and ultrasonography-guided fine-needle aspiration biopsy together with scintigraphy are probably the most adequate tools for diagnosis. After thyroidectomy, treatment with iodine-131 is routinely performed in a nuclear medicine therapy institution as a standard procedure in most of the cases with regard to histology. In case of iodine positive metastases, repeated therapies can be performed in order to reduce tumour burden. In the follow up of DTC thyroglobulin (tumour marker), ultrasound and diagnostic whole body scan are established procedures. With the development of SPECT/CT and PET/CT (18F-FDG, 68Ga-somatostatin receptor) combining functional and anatomic imaging the nuclear medicine spectrum has further increased.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 19-20/2012

Wiener Medizinische Wochenschrift 19-20/2012 Zur Ausgabe